Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Revolution Medicines, Inc., Charles River Laboratories International or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Revolution Medicines, Inc., Charles River Laboratories International and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Revolution Medicines, Inc., Charles River Laboratories International and Inc.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children’s Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Latest Biotechnology and Revolution Medicines, Inc., Charles River Laboratories International, Inc. Stock News

As of September 1, 2026, Revolution Medicines, Inc. had a $45.0 billion market capitalization, compared to the Biotechnology median of $282.5 million. Revolution Medicines, Inc.’s stock is NA in 2026, NA in the previous five trading days and up 452.73% in the past year.

Currently, Revolution Medicines, Inc. does not have a price-earnings ratio. Revolution Medicines, Inc.’s trailing 12-month revenue is $0.0 million with a % net profit margin. As of September 1, 2026, Revolution Medicines, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-9.748 per share for the current fiscal year. Revolution Medicines, Inc. does not currently pay a dividend.

Currently, Charles River Laboratories International, Inc. does not have a price-earnings ratio. Charles River Laboratories International, Inc.’s trailing 12-month revenue is $4.0 billion with a -6.0% net profit margin. Year-over-year quarterly sales growth most recently was -2.7%. Analysts expect adjusted earnings to reach $11.318 per share for the current fiscal year. Charles River Laboratories International, Inc. does not currently pay a dividend.

How We Compare Revolution Medicines, Inc., Charles River Laboratories International and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Revolution Medicines, Inc., Charles River Laboratories International and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Revolution Medicines, Inc., Charles River Laboratories International and Inc. Stock Value Grades

Company	Ticker	Value
Revolution Medicines, Inc.	RVMD	na
Charles River Laboratories International, Inc.	CRL	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Revolution Medicines, Inc. does not have a meaningful Value Score. Charles River Laboratories International, Inc. has a Value Score of 24, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Revolution Medicines, Inc., Charles River Laboratories International or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Revolution Medicines, Inc., Charles River Laboratories International or Inc. is the better investment when it comes to value.

Revolution Medicines, Inc., Charles River Laboratories International and Inc. Growth Grades

Company	Ticker	Growth
Revolution Medicines, Inc.	RVMD	na
Charles River Laboratories International, Inc.	CRL	B

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Revolution Medicines, Inc. does not have a meaningful Growth Score. Charles River Laboratories International, Inc. has a Growth Score of 77, which is Strong.

The Growth Stock Winner: Undetermined

If you are strictly a growth investor, you may want to add Charles River Laboratories International, Inc. to your watch list. However, because only one of the companies in this comparison has a valid Growth Grade, we cannot call it a clear winner. Evaluation of the other grades for both companies is necessary in order to understand which stock is the better investment based on AAII’s proprietary scores and analysis.

Revolution Medicines, Inc., Charles River Laboratories International and Inc.’s Momentum Grades

Company	Ticker	Momentum
Revolution Medicines, Inc.	RVMD	A
Charles River Laboratories International, Inc.	CRL	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Revolution Medicines, Inc. has a Momentum Score of 98, which is Very Strong. Charles River Laboratories International, Inc. has a Momentum Score of 93, which is Very Strong.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both Revolution Medicines, Inc., Charles River Laboratories International and Inc. have a grade of A. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

Other Revolution Medicines, Inc., Charles River Laboratories International and Inc. Grades

In addition to Momentum, Value and Growth, A+ Investor also provides grades for Estimate Revisions and Quality.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Revolution Medicines, Inc., Charles River Laboratories International and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Revolution Medicines, Inc., Charles River Laboratories International or Inc. Stock?

Overall, Revolution Medicines, Inc. stock has a Value Score of , Growth Score of and Momentum Score of 98.

Charles River Laboratories International, Inc. stock has a Value Score of 24, Growth Score of 77 and Momentum Score of 93.

Comparing Revolution Medicines, Inc., Charles River Laboratories International and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.